Study of the Relationships Between Apolipoprotein B-48 Kinetics and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With the Metabolic Syndrome (SMB48)

NCT01829945 | Completed

• 1 other identifier: INAF-129-05-02
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Several lines of evidence indicate that a significant proportion of cardiovascular disease (CVD) events are attributable to the presence of a cluster of metabolic abnormalities and perturbations, defined as the metabolic syndrome. It has been estimated that approximately 25% of the North American adult population is living with the metabolic syndrome. Recent studies show that overaccumulation of atherogenic triglyceride-rich lipoproteins (TRL) seen in insulin-resistant patients is partly due to increased production rate of intestinally derived apolipoproteinB-48-containing lipoproteins. This is of interest because substantial evidence exists indicating that elevated levels of intestinal lipoproteins are associated with increased CVD risk. However, as indicated in the body of this grant proposal, the underlying mechanisms that lead to intestinal overproduction of lipoproteins in insulin-resistant states are poorly understood. The general objective of the proposed research is to investigate the mechanisms by which the metabolic syndrome affects apolipoproteinB-48 secretion in human. The primary hypothesis is that insulin resistance will be associated with higher levels of intestinal lipoproteins because of an increased secretion of these particles.

Conditions

Metabolic Syndrome X

Outcome Measures

Primary Outcomes (1)

• Change in TRL apolipoproteinB-48 production rate.

  Week 1

Secondary Outcomes (3)

• Changes in duodenal expression of genes that regulate intestinal lipid absorption.

  Week 1

• Change in duodenal expression of genes that regulate intestinal lipid synthesis.

  Week 1

• Change in synthesis of apolipoproteinB-48 containing lipoproteins (Microsomal triglyceride transfer protein (MTP), apolipoproteinB-48).

  Week 1

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

community sample

You may qualify if:

• Subjects with metabolic syndrome:
• Men aged between 18-60 years
• Waist circumference \>102
• HDL-cholesterol \< 1.1 mmol/L
• Triglycerides \> 1.7 mmol/L
• Fasting blood glucose \>6.1 mmol/L
• Normal blood pressure (\<130/85)
• Controls:
• Men aged between 18-60 years
• Waist circumference \>102
• HDL-cholesterol \> 1.1 mmol/L
• Triglycerides \< 1.7 mmol/L
• Fasting blood glucose \<6.1 mmol/L
• Normal blood pressure (\<130/85)

You may not qualify if:

• Women
• Men \< 18 or \> 60 years
• Smokers (\> 1 cigarette/day)
• Body weight variation \> 10% during the last 6 months prior to the study baseline
• Subjects with a previous history of cardiovascular disease
• Subjects with Type 2 diabetes
• Subjects with a monogenic dyslipidemia
• Subjects on hypertension medications or medications known to affect lipoprotein metabolism or the integrity of gastrointestinal mucosa
• Subjects with endocrine or gastrointestinal disorders
• History of alcohol or drug abuse within the past 2 years
• Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study

Sponsors & Collaborators

• Laval University: lead
• Canadian Institutes of Health Research (CIHR): collaborator

Study Sites (1)

Institute of Nutrition and Functional Foods (INAF)

Québec, Quebec, G1V 0A6, Canada

Location

Biospecimen

Retention: SAMPLES WITH DNA

Serum Plasma Intestinal tissue

MeSH Terms

Conditions

Metabolic Syndrome

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Patrick Couture, MD, FRCP, PhD

  Laval University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, FRCP, PhD

Study Record Dates

• First Submitted: April 8, 2013
• First Posted: April 11, 2013
• Study Start: October 1, 2009
• Primary Completion: February 1, 2010
• Study Completion: February 1, 2011
• Last Updated: April 11, 2013

Record last verified: 2013-04

Locations

CA (1)